You have 9 free searches left this month | to do more

azacitidine

Azacitidine is a drug used to treat Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome, and other conditions. Azacitidine is being actively studied in 153 studies and prior, has been studied in 97.

Top SponsorsTop SitesTop Investigators
M.D. Anderson Cancer CenterM D Anderson Cancer CenterBrian Jonas
National Cancer Institute (NCI)MD Anderson Cancer CenterBart Scott
CelgeneWashington University School of MedicineBruno C. Medeiros
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
  • High Grade Myelodysplastic Syndromes
  • Aurora, Colorado
    Universtiy of Colorado Denver
2021-10-19
Oct 19, 2021
N
Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Los Angeles, California
  • +3 more
2022-03-25
Mar 25, 2022
A
Recruiting
  • Recurrent IDH1/2 Mutated Glioma
  • Azacitidine
  • Paris, France
    Pitie Salpetriere Hospital
2022-03-28
Mar 28, 2022
H
Recruiting
  • Myeloid Malignancy
  • azacitidine
  • Detroit, Michigan
    Henry ford hospital
2021-12-23
Dec 23, 2021
W
Active, not recruiting
  • Myelodysplastic Syndromes
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-03-23
Mar 23, 2022
F
Withdrawn
  • Myelodysplastic Syndrome (MDS)
  • (no location specified)
2021-07-20
Jul 20, 2021
U
Recruiting
  • Acute Myeloid Leukemia
  • Aurora, Colorado
    Universtiy of Colorado Hospital
2022-02-15
Feb 15, 2022
U
Not yet recruiting
  • Myeloproliferative Neoplasm
  • BCR-ABL Negative
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-09-29
Sep 29, 2021
A
Not yet recruiting
  • Higher Risk Myelodysplastic Syndrome
  • Chronic Myelomonocytic Leukemia
  • AMG 176
  • Azacitidine
  • (no location specified)
2022-01-13
Jan 13, 2022
G
Recruiting
  • Acute Myeloid Leukemia
  • NanJing, China
    Department of Hematology, Zhongda Hospital, Medical School of So
2022-03-22
Mar 22, 2022
I
Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
2021-11-21
Nov 21, 2021
T
Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Anti-PD-1 monoclonal antibody
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
2021-12-21
Dec 21, 2021
R
Active, not recruiting
  • Pancreas Cancer
  • New York, New York
    Columbia University Irving Medical Center
2021-10-20
Oct 20, 2021
U
Recruiting
  • Breast Cancer Female
  • Breast Cancer Invasive
  • Azacitidine
  • Chicago, Illinois
  • +1 more
2022-01-24
Jan 24, 2022
M
Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Azacitidine
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
2021-10-06
Oct 6, 2021
S
Not yet recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • (no location specified)
2021-11-29
Nov 29, 2021
L
Recruiting
  • Acute Myeloid Leukemia
  • Lanzhou, Gansu, China
    The First Hospital of Lanzhou University
2021-10-07
Oct 7, 2021
M
Recruiting
  • Acute Myeloid Leukemia
  • Duarte, California
  • +2 more
2022-01-21
Jan 21, 2022
M
Active, not recruiting
  • Melanoma and Other Malignant Neoplasms of Skin
  • Metastatic Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-02-04
Feb 4, 2022
A
Not yet recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • (no location specified)
2022-02-22
Feb 22, 2022
M
Recruiting
  • Chronic Myelomonocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-12-21
Dec 21, 2021
C
Completed
  • Myelodysplastic Syndromes
  • +2 more
  • Azacitidine
  • Ascorbic acid
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
2021-08-04
Aug 4, 2021
M
Recruiting
  • Chronic Myelomonocytic Leukemia-0
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-18
Jan 18, 2022